Free Trial
NYSE:LLY

Eli Lilly and Company (LLY) Stock Price, News & Analysis

$905.10
-1.08 (-0.12%)
(As of 09/18/2024 ET)

About Eli Lilly and Company Stock (NYSE:LLY)

Key Stats

Today's Range
$903.46
$915.50
50-Day Range
$772.14
$960.02
52-Week Range
$516.57
$972.53
Volume
1.78 million shs
Average Volume
3.02 million shs
Market Capitalization
$860.21 billion
P/E Ratio
133.30
Dividend Yield
0.57%
Price Target
$977.35
Consensus Rating
Moderate Buy

Company Overview

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

Eli Lilly and Company Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks

Overall MarketRank™: 95th Percentile

Eli Lilly and Company scored higher than 95% of companies evaluated by MarketBeat, and ranked 88th out of 1,015 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eli Lilly and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.84, and is based on 16 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Eli Lilly and Company has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Eli Lilly and Company's stock forecast and price target.
  • Earnings Growth

    Earnings for Eli Lilly and Company are expected to grow by 45.36% in the coming year, from $16.49 to $23.97 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eli Lilly and Company is 133.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.09.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eli Lilly and Company is 133.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.54.

  • Price to Earnings Growth Ratio

    Eli Lilly and Company has a PEG Ratio of 2.79. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Eli Lilly and Company has a P/B Ratio of 79.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Eli Lilly and Company's valuation and earnings.
  • Percentage of Shares Shorted

    0.74% of the float of Eli Lilly and Company has been sold short.
  • Short Interest Ratio / Days to Cover

    Eli Lilly and Company has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eli Lilly and Company has recently decreased by 0.48%, indicating that investor sentiment is improving.
  • Dividend Yield

    Eli Lilly and Company has a dividend yield of 0.56%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Eli Lilly and Company does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Eli Lilly and Company is 76.58%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Eli Lilly and Company will have a dividend payout ratio of 21.69% next year. This indicates that Eli Lilly and Company will be able to sustain or increase its dividend.

  • Read more about Eli Lilly and Company's dividend.
  • Percentage of Shares Shorted

    0.74% of the float of Eli Lilly and Company has been sold short.
  • Short Interest Ratio / Days to Cover

    Eli Lilly and Company has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eli Lilly and Company has recently decreased by 0.48%, indicating that investor sentiment is improving.
  • News Sentiment

    Eli Lilly and Company has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 57 news articles for Eli Lilly and Company this week, compared to 41 articles on an average week.
  • Search Interest

    Only 96 people have searched for LLY on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.
  • MarketBeat Follows

    Only 64 people have added Eli Lilly and Company to their MarketBeat watchlist in the last 30 days. This is a decrease of -26% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Eli Lilly and Company insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $418,732,178.00 in company stock.

  • Percentage Held by Insiders

    Only 0.13% of the stock of Eli Lilly and Company is held by insiders.

  • Percentage Held by Institutions

    82.53% of the stock of Eli Lilly and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Eli Lilly and Company's insider trading history.
Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.

LLY Stock News Headlines

Galicia, Spain; June 8, 2020 : Smart phone showing Merck logo on screen and pills and syringe on blue background
Is Merck Stock Undervalued After Its Colossal Earnings Growth? (LLY)
Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant?
A lab technician prepares DNA samples for analysis at Complete Genomics in San Jose, Calif
Congress targets Chinese influence in health tech. It could come with tradeoffs
A San Jose-based biotechnology company that helps doctors detect genetic causes for cancer is among those that could be cut out of the U.S. market over ties to China
Biden’s Capital Gains Tax to Devastate Savings!
Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.
Photo of a couple placing a soft down in their living room, sofa at an upward angle stymbolizing rising stock prices.
Invest While You Can: Pullbacks on These 3 Stocks Won’t Last Long
Three stocks stand out for investors to consider as they recently had big selloffs. There are fundamental reasons to believe that these discounts won't last
weight loss injection with measuring tape Eli Lilly
Eli Lilly’s Path to the Next Trillion Market Capitalization
Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.
Eli Lilly and Company (NYSE:LLY) Shares Up 0% After Analyst Upgrade
See More Headlines

LLY Stock Analysis - Frequently Asked Questions

Eli Lilly and Company's stock was trading at $582.92 on January 1st, 2024. Since then, LLY shares have increased by 55.3% and is now trading at $905.10.
View the best growth stocks for 2024 here
.

Eli Lilly and Company (NYSE:LLY) released its quarterly earnings results on Thursday, August, 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a trailing twelve-month return on equity of 67.52% and a net margin of 18.86%.

The following companies are subsidiaries of Eli Lilly and Company: Protomer Technologies, Prevail Therapeutics Inc., Disarm Therapeutics, Disarm Therapeutics, Dermira, Loxo Oncology, CoLucid Pharmaceuticals, and more.

Eli Lilly and Company's top institutional investors include Primecap Management Co. CA (2.06%), Legal & General Group Plc (0.75%), Bank of New York Mellon Corp (0.69%) and Dimensional Fund Advisors LP (0.38%). Insiders that own company stock include Lilly Endowment Inc, Jackson P Tai, Anne E White, Patrik Jonsson, Johna Norton, Alonzo Weems, Donald A Zakrowski, Acquisition Corp Kearny, Marschall S Runge and Ilya Yuffa.
View institutional ownership trends
.

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eli Lilly and Company investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY) and Walt Disney (DIS).

Company Calendar

Last Earnings
8/08/2024
Ex-Dividend for 9/10 Dividend
8/15/2024
Dividend Payable
9/10/2024
Today
9/18/2024
Next Earnings (Estimated)
11/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
53245710
Employees
43,000
Year Founded
1876

Price Target and Rating

Average Stock Price Target
$977.35
High Stock Price Target
$1,125.00
Low Stock Price Target
$710.00
Potential Upside/Downside
+8.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.84
Research Coverage
19 Analysts

Profitability

Net Income
$5.24 billion
Pretax Margin
23.09%

Debt

Sales & Book Value

Annual Sales
$38.92 billion
Cash Flow
$7.50 per share
Book Value
$11.44 per share

Miscellaneous

Free Float
949,169,000
Market Cap
$860.21 billion
Optionable
Optionable
Beta
0.42

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 10, 2024. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

Eli Lilly and Company
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

  • Eli Lilly and Co reported an impressive quarterly earnings data, surpassing the consensus estimate by a significant margin, indicating strong financial performance.
  • The company has a high return on equity of 67.52%, showcasing efficient utilization of shareholder funds to generate profits.
  • Insider transactions show major shareholders selling shares at a high price, suggesting confidence in the company's future growth prospects.
  • Eli Lilly and Co has a stable dividend payout ratio of 76.58%, providing investors with a consistent income stream.
  • Institutional investors have been increasing their stakes in the company, indicating confidence in its long-term potential.

Eli Lilly and Company
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

  • The company's debt-to-equity ratio of 1.74 is relatively high, indicating a higher level of financial leverage which may pose risks during economic downturns.

This page (NYSE:LLY) was last updated on 9/18/2024 by MarketBeat.com Staff
From Our Partners